Ovarian Cancer

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.

Researchers at Texas A&M University have developed an organ-on-a-chip that they said could change the way clinicians approach ovarian and other cancer treatment.

A trial designed to evaluate maveropepimut-S for women with advanced recurrent ovarian cancer demonstrated encouraging activity, according to the agent’s manufacturer.

Although 5-year survival rates have increased for multiple cancer types among adolescents and young adults, little or no improvement has been observed for some common malignancies in this population, according to findings published in Cancer.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, spoke with Healio about findings from a study examining survival with longer vs. shorter duration of bevacizumab therapy in patients with advanced ovarian cancer.

In this video, Janos L. Tanyi, MD, PhD, discussed findings from the “very interesting” VITAL study that assessed the potential of a novel vaccine as front-line maintenance therapy for women with ovarian cancer.

In this video, Janos L. Tanyi, MD, PhD, assistant professor in the department of gynecologic oncology at the University of Pennsylvania, spoke with Healio about a study evaluating the use of mirvetuximab soravtansine for recurrent ovarian cancer.

In this video, Janos L. Tanyi, MD, PhD discussed findings from a study evaluating pafolacianine sodium combined with intraoperative near-infrared fluorescence imaging in patients with ovarian cancer.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about research that demonstrated the potential of a novel vaccine as front-line maintenance therapy in advanced-stage ovarian cancer.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, discussed “hotly anticipated” results from the BOOST trial evaluating the potential benefits of extending bevacizumab therapy plus chemotherapy in newly diagnosed ovarian cancer.